title: Efficacy, safety, and tolerability of oxcarbazepine monotherapy.
abstract: OBJECTIVE
  This prospective, open-label, multicenter study evaluated the efficacy and tolerability of oxcarbazepine as monotherapy in patients with partial seizures who switched from their current antiepileptic drug (AED) monotherapy because of lack of efficacy or poor tolerability.
  
  
  METHODS
  Patients (>or=12 years old) experiencing 2-40 seizures per month while receiving an AED were included. During a 16-week treatment phase, oxcarbazepine was initiated (8-10mg/kg for children; 600 mg/day for adults) and titrated up over 4 weeks while the existing AED was tapered off. Improvement in seizure frequency (defined as >or=50% reduction compared with baseline) was evaluated for all patients, as well as the subgroups of patients switched due to poor tolerability or lack of efficacy.
  
  
  RESULTS
  Overall, 52% of patients experienced a 50% reduction in seizure frequency, 35% had a >or=75% reduction, and 18% were seizure-free. The most frequent (>10%) adverse events were dizziness, nausea, headache, somnolence, and fatigue. Overall, 17% of patients prematurely withdrew because of an adverse event; 62% of these withdrawals occurred during the conversion period.
  
  
  CONCLUSIONS
  Oxcarbazepine as monotherapy may be a favorable treatment option for patients with partial seizures or poor tolerability of their existing monotherapy regimen.
authors.affiliation: Premiere Research Institute, West Palm Beach, FL, USA. eneuro@aol.com <eneuro@aol.com>
authors.forename: Walter
authors.initials: W
authors.lastname: Martinez
authors.forename: Allan
authors.initials: A
authors.lastname: Ingenito
authors.forename: Mark
authors.initials: M
authors.lastname: Blakeslee
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Barkley
authors.forename: Kevin
authors.initials: K
authors.lastname: McCague
authors.forename: Joseph
authors.initials: J
authors.lastname: D'Souza
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D011446:Prospective Studies
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine